Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663039 | 0.90 | PDGFRA (0.62) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL2748115 | 0.84 | KDR (0.62) | PDGFRBPDGFRAEGFRKDR | |
| SCHEMBL925876 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29573413 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL19957123 | 0.80 | PDGFRA (0.49) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL7486400 | 0.79 | FGFR2 (0.84) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL168048 | 0.78 | PDGFRB (0.79) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL19957134 | 0.78 | KDR (0.47) | PDGFRBPDGFRAFGFR2KDR | |
| SCHEMBL7482292 | 0.78 | PDGFRA (0.78) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL19957033 | 0.77 | KDR (0.60) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | PDGFRB 54/4885PDGFRA 52/4885FGFR2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.